En undersøgelse for at undersøge effektiviteten og sikkerheden af anifrolumab hos voksne med kronisk og/eller subakut kutan lupus erythematosus (LAVENDER)
Et multicenter, randomiseret, dobbeltblindt, placebokontrolleret, fase III-studie for at evaluere effektiviteten og sikkerheden af anifrolumab hos voksne med kronisk og/eller subakut kutan lupus erythematosus, som er refraktære og/eller intolerante over for antimalariaterapi
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Ciudad de Buenos Aires, Argentina, 1221
- Research Site
-
Córdoba, Argentina, 5000
- Research Site
-
Córdoba, Argentina, X5004BAL
- Research Site
-
Quilmes, Argentina, 1878
- Research Site
-
San Miguel, Argentina, 1663
- Research Site
-
-
-
-
-
Kogarah, Australien, 3168
- Research Site
-
Melbourne, Australien, 3004
- Research Site
-
Mitcham, Australien, 3132
- Research Site
-
Westmead, Australien, 2145
- Research Site
-
Woolloongabba, Australien, 04102
- Research Site
-
-
-
-
-
Belo Horizonte, Brasilien, 30150-221
- Research Site
-
Porto Alegre, Brasilien, 90035903
- Research Site
-
Rio de Janeiro, Brasilien, 22470-220
- Research Site
-
Salvador, Brasilien, 40150-150
- Research Site
-
São Paulo, Brasilien, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bulgarien, 1784
- Research Site
-
Sofia, Bulgarien, 1463
- Research Site
-
Sofia, Bulgarien, 1528
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Research Site
-
Toronto, Ontario, Canada, M5T 2S8
- Research Site
-
-
-
-
-
Osorno, Chile, 200025
- Research Site
-
Santiago, Chile, 7500571
- Research Site
-
Santiago, Chile, 130021
- Research Site
-
-
-
-
-
Barranquilla, Colombia, 080020
- Research Site
-
Bogotá, Colombia, 110221
- Research Site
-
-
-
-
-
Aarhus, Danmark, 641-8510
- Research Site
-
Copenhagen, Danmark, 2100
- Research Site
-
-
-
-
-
Cambridge, Det Forenede Kongerige, CB2 0QQ
- Research Site
-
Leeds, Det Forenede Kongerige, LS2 9JT
- Research Site
-
London, Det Forenede Kongerige, NW1 2PG
- Research Site
-
London, Det Forenede Kongerige, SE5 9RS
- Research Site
-
London, Det Forenede Kongerige, SE1 7EH
- Research Site
-
London, Det Forenede Kongerige, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Det Forenede Kongerige, NE1 4LP
- Research Site
-
-
-
-
-
Iloilo City, Filippinerne, 5000
- Research Site
-
Lipa, Filippinerne, 4217
- Research Site
-
Manila, Filippinerne, 1000
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85028
- Research Site
-
-
California
-
Covina, California, Forenede Stater, 91722
- Research Site
-
La Jolla, California, Forenede Stater, 92037
- Research Site
-
Los Angeles, California, Forenede Stater, 90045
- Research Site
-
Los Angeles, California, Forenede Stater, 90089
- Research Site
-
Orange, California, Forenede Stater, 92868
- Research Site
-
San Francisco, California, Forenede Stater, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33309
- Research Site
-
Miami, Florida, Forenede Stater, 33174
- Research Site
-
Plantation, Florida, Forenede Stater, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Research Site
-
Chicago, Illinois, Forenede Stater, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Research Site
-
Boston, Massachusetts, Forenede Stater, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Research Site
-
Bloomfield Hills, Michigan, Forenede Stater, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Forenede Stater, 10028
- Research Site
-
Rochester, New York, Forenede Stater, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28207
- Research Site
-
Statesville, North Carolina, Forenede Stater, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22903
- Research Site
-
Roanoke, Virginia, Forenede Stater, 24016
- Research Site
-
-
-
-
-
Bois-Guillaume, Frankrig, 76031
- Research Site
-
Dijon, Frankrig, 21000
- Research Site
-
Lyon, Frankrig, 69437
- Research Site
-
Montivilliers, Frankrig, 76290
- Research Site
-
Nantes, Frankrig, 44000
- Research Site
-
Paris, Frankrig, 75010
- Research Site
-
Paris, Frankrig, 75014
- Research Site
-
Paris, Frankrig, 75013
- Research Site
-
Paris, Frankrig, 75970
- Research Site
-
Poitiers, Frankrig, 86000, FR
- Research Site
-
Toulouse, Frankrig, 31059
- Research Site
-
-
-
-
-
Athens, Grækenland, 12462
- Research Site
-
Athens, Grækenland, 16121
- Research Site
-
-
-
-
-
Breda, Holland, 4818 CK
- Research Site
-
Rotterdam, Holland, 3015 GD
- Research Site
-
-
-
-
-
Brescia, Italien, 25123
- Research Site
-
Cona, Italien, 44124
- Research Site
-
Florence, Italien, 50121
- Research Site
-
Milan, Italien, 20132
- Research Site
-
Naples, Italien, 80138
- Research Site
-
Reggio Emilia, Italien, 42123
- Research Site
-
Roma, Italien, 00144
- Research Site
-
Rome, Italien, 00168
- Research Site
-
-
-
-
-
Chūōku, Japan, 104-8560
- Research Site
-
Fukuoka, Japan, 812-8582
- Research Site
-
Kanazawa, Japan, 920-8641
- Research Site
-
Kita-gun, Japan, 761-0793
- Research Site
-
Nagoya, Japan, 457-8510
- Research Site
-
Nagoya, Japan, 467-8602
- Research Site
-
Wakayama, Japan, 641-8510
- Research Site
-
Yokohama, Japan, 232-0024
- Research Site
-
tabashi City, Japan, 173-8606
- Research Site
-
-
-
-
-
Changchun, Kina, 130021
- Research Site
-
Changsha, Kina, 410011
- Research Site
-
Chengdu, Kina, 610021
- Research Site
-
Chongqing, Kina, 400016
- Research Site
-
Dongguan, Kina, 523059
- Research Site
-
Guangzhou, Kina, 510120
- Research Site
-
Heilongjiang, Kina, 150086
- Research Site
-
Jinan, Kina, 250022
- Research Site
-
Shanghai, Kina, 200025
- Research Site
-
Shanghai, Kina, 200443
- Research Site
-
Shenzhen, Kina, 518053
- Research Site
-
Shenzhen, Kina, 518020
- Research Site
-
Shenzhen, Kina, 518052
- Research Site
-
Zhuzhou, Kina, 412007
- Research Site
-
Ürümqi, Kina, CN-830004
- Research Site
-
-
-
-
-
Guadalajara, Mexico, 44340
- Research Site
-
Guadalajara, Mexico, 44610
- Research Site
-
Mexico City, Mexico, 07760
- Research Site
-
Veracruz, Mexico, 91910
- Research Site
-
-
-
-
-
Papatoetoe, New Zealand, 2025
- Research Site
-
-
-
-
-
Katowice, Polen, 40-851
- Research Site
-
Kielce, Polen, 25-316
- Research Site
-
Ossy, Polen, 40-027
- Research Site
-
Rzeszów, Polen, 35-055
- Research Site
-
Warsaw, Polen, 02-637
- Research Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Research Site
-
Lisbon, Portugal, 1649-035
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Bucharest, Rumænien, 020125
- Research Site
-
Iași, Rumænien, 700291
- Research Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Research Site
-
Kragujevac, Serbien, 34000
- Research Site
-
-
-
-
-
Košice, Slovakiet, 04001
- Research Site
-
Piešťany, Slovakiet, 92101
- Research Site
-
-
-
-
-
Barcelona, Spanien, 8035
- Research Site
-
Barcelona, Spanien, 08025
- Research Site
-
Castellon, Spanien, 12004
- Research Site
-
Granada, Spanien, 18012
- Research Site
-
L'Hospitalet de Llobregat, Spanien, 08907
- Research Site
-
Las Palmas de Gran Canaria, Spanien, 35010
- Research Site
-
Madrid, Spanien, 28034
- Research Site
-
Madrid, Spanien, 28041
- Research Site
-
Madrid, Spanien, 28040
- Research Site
-
Madrid, Spanien, 28006
- Research Site
-
Majadahonda, Spanien, 28222
- Research Site
-
Salamanca, Spanien, 37007
- Research Site
-
Seville, Spanien, 41014
- Research Site
-
Valencia, Spanien, 46014
- Research Site
-
Valencia, Spanien, 46017
- Research Site
-
Vigo, Spanien, 36200
- Research Site
-
-
-
-
-
Cape Town, Sydafrika, 7500
- Research Site
-
Johannesburg, Sydafrika, 2193
- Research Site
-
-
-
-
-
Seoul, Sydkorea, 03080
- Research Site
-
Seoul, Sydkorea, 06591
- Research Site
-
Seoul, Sydkorea, 06973
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Research Site
-
Taichung, Taiwan, 404
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10330
- Research Site
-
Bangkok, Thailand, 10700
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Khlong Luang, Thailand, 12120
- Research Site
-
Khon Kaen, Thailand, 40002
- Research Site
-
-
-
-
-
Cordaleo, Tyrkiet (Türkiye), 35575
- Research Site
-
Istanbul, Tyrkiet (Türkiye), 34098
- Research Site
-
Kayseri, Tyrkiet (Türkiye), 38039
- Research Site
-
Samsun, Tyrkiet (Türkiye), 55270
- Research Site
-
-
-
-
-
Berlin, Tyskland, 10117
- Research Site
-
Bochum, Tyskland, 44791
- Research Site
-
Dresden, Tyskland, 01307
- Research Site
-
Erlangen, Tyskland, 91054
- Research Site
-
Essen, Tyskland, 45147
- Research Site
-
Freiburg im Breisgau, Tyskland, 79104
- Research Site
-
Hanover, Tyskland, 30625
- Research Site
-
Kiel, Tyskland, 24105
- Research Site
-
Leipzig, Tyskland, 04103
- Research Site
-
Mainz, Tyskland, 55131
- Research Site
-
Marburg, Tyskland, 35043
- Research Site
-
Regensburg, Tyskland, 93053
- Research Site
-
Wuppertal, Tyskland, 42283
- Research Site
-
-
-
-
-
Graz, Østrig, 8036
- Research Site
-
Innsbruck, Østrig, 6020
- Research Site
-
Linz, Østrig, 4020
- Research Site
-
Vienna, Østrig, 1130
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Placebo komparator: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Tidsramme: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in total CLASI-A score
Tidsramme: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Tidsramme: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Tidsramme: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Tidsramme: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Tidsramme: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Tidsramme: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Tidsramme: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Tidsramme: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Tidsramme: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Tidsramme: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Tidsramme: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Tidsramme: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Tidsramme: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Tidsramme: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Tidsramme: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with adverse events
Tidsramme: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- D346BC00001
- 2021-003698-70 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .